HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $49
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor maintains a Buy rating on Cartesian Therapeutics (NASDAQ:RNAC) but lowers the price target from $54 to $49.
July 03, 2024 | 5:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor maintains a Buy rating on Cartesian Therapeutics but lowers the price target from $54 to $49.
The Buy rating suggests continued confidence in Cartesian Therapeutics' potential, but the lowered price target indicates some caution regarding its short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100